Mass Spectrometry Imaging Market Report 2025

The mass spectrometry imaging market size has grown strongly in recent years. It will grow from $2.65 billion in 2024 to $2.88 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing adoption in pharmaceutical research, rising demand for personalized medicine, rise in cancer diagnostics applications, increase in drug discovery and development activities, and increasing funding for biomedical research.

The mass spectrometry imaging market size is expected to see strong growth in the next few years. It will grow to $4.07 billion in 2029 at a compound annual growth rate (CAGR) of 9%. The growth in the forecast period can be attributed to a growing focus on spatial omics research, an increasing use in biomarker discovery, a rising integration with artificial intelligence tools, expanding applications in clinical diagnostics, and an increase in demand for high-resolution imaging techniques. Major trends in the forecast period include advancement in high-resolution mass spectrometry technologies, advanced imaging software integration, innovation in sample preparation techniques, advancement in hybrid imaging modalities, and advanced automation in data analysis workflows.

The forecast of 9% growth over the next five years reflects a slight reduction of 0.2% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. biomedical research by inflating prices ofmatrix-assisted laser desorption/ionization time-of-flight mass spectrometry and imaging software platforms manufactured in the U.S. and Germany, resulting in delayed proteomics research and higher analytical chemistry costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing demand for personalized medicine is anticipated to drive the growth of the mass spectrometry imaging market in the future. Personalized medicine tailors healthcare treatments to individual patients based on their genetic makeup, environment, and lifestyle, aiming to improve treatment effectiveness. The growth of personalized medicine is fueled by advances in genomics, which allow for targeted treatments based on genetic profiles, enhancing efficacy and minimizing side effects. Mass spectrometry imaging aids personalized medicine by generating detailed molecular maps of tissues, assisting in the identification of disease biomarkers, and facilitating the creation of targeted therapies designed for individual patient profiles. For example, in February 2024, the Personalized Medicine Coalition, a non-profit organization based in the US, reported that the FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. As a result, the increasing demand for personalized medicine is contributing to the expansion of the mass spectrometry imaging market.

Leading companies in the mass spectrometry imaging (MSI) market are concentrating on developing advanced technologies, such as desorption electrospray ionization (DESI), to offer more precise and detailed molecular analysis for various applications. DESI is an ionization technique that extracts ions from surfaces in ambient conditions using a charged solvent spray, allowing for direct analysis of solid samples, including tissues, without the need for sample preparation or extraction. In June 2023, Waters Corporation, a US-based manufacturer of analytical laboratory instruments, introduced a targeted imaging mass spectrometer. This innovation enhances tissue analysis by improving sensitivity and speed, providing more precise small-molecule drug analysis and offering higher resolution in targeted imaging. The device enables faster detection, improving biological studies' efficiency. It enhances accuracy and effectiveness, significantly benefiting research efforts. This advancement supports drug development and biological research by providing high-quality, detailed data.

In March 2023, Agilent Technologies Inc., a US-based company specializing in advanced analytical, research, and diagnostic solutions, acquired e-MSion for an undisclosed sum. The acquisition aims to enhance Agilent's mass spectrometry tools by incorporating advanced electron capture dissociation (ECD) technology, which will help researchers obtain more precise and detailed information about complex molecules such as proteins. e-MSion is an early-stage company based in the US that focuses on electron capture dissociation (ECD) technology, improving the accuracy of mass spectrometers in analyzing complex molecules.

Major players in the mass spectrometry imaging market are Thermo Fisher Scientific Inc., Danaher Corporation, Hitachi High-Tech Corporation, Shimadzu Corporation, Waters Corporation, Bruker Corporation, Horiba Scientific, JEOL Ltd., SCIEX, Analytik Jena AG, Standard BioTools, TOFWERK AG, Advion Inc., MassTech Inc., CovalX AG, ImaBiotech SAS, MassAnalytica LLC, Ionwerks Inc., Biognosys AG, Spectroswiss Sàrl.

North America was the largest region in the mass spectrometry imaging market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the mass spectrometry imaging market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The mass spectrometry imaging market consists of revenues earned by entities by providing services such as quantitative analysis, molecular profiling, chemical imaging, and pathology integration. The market value includes the value of related goods sold by the service provider or included within the service offering. The mass spectrometry imaging market includes sales of specialized detectors, mass spectrometers, testing kits, and sample preparation systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The mass spectrometry imaging market research report is one of a series of new reports that provides mass spectrometry imaging market statistics, including mass spectrometry imaging industry global market size, regional shares, competitors with a mass spectrometry imaging market share, mass spectrometry imaging market segments, market trends and opportunities, and any further data you may need to thrive in the mass spectrometry imaging industry. This mass spectrometry imaging market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Mass spectrometry imaging (MSI) is a technique that combines mass spectrometry with imaging to visualize the distribution of chemical compounds within biological or material samples. This method allows for the detection of molecules such as lipids, proteins, and metabolites in tissue sections. MSI offers valuable molecular insights that contribute to the understanding of disease mechanisms, tissue structure, and the identification of biomarkers. Its primary goal is to link molecular data with spatial context to provide a deeper insight into biological systems.

Mass spectrometry imaging's key product categories include instruments, consumables, and services. Instruments encompass the devices or equipment used in mass spectrometry imaging to assess the chemical composition of samples by measuring the mass-to-charge ratio of ions. The technology employs various techniques such as matrix-assisted laser desorption or ionization (MALDI), secondary ion mass spectrometry (SIMS), desorption electrospray ionization (DESI), magnetic sector mass spectrometry, and time-of-flight mass spectrometry (TOFMS), among others. These methods have numerous applications, including proteomics, metabolomics, and glycomics, and are utilized by a range of end-users, including pharmaceutical and biotechnology firms, academic institutions, and government organizations.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.